CRT PREDICTS | Comparison of Angiography-Derived Fractional Flow Reserve-Guided and Intravascular Ultrasound-Guided Percutaneous Coronary Intervention Strategies | The FLAVOUR II Trial

Sunday, March 9, 2025

10:20 AM - 10:40 AM ET

Moderator(s)

Gregg W. Stone, MD, FACC, MSCAI

Physician
Mount Sinai
New York, New York, United States

Disclosure information not submitted.
Ron Waksman, MD, MSCAI

Director, Cardiovascular Research and Advanced Education
MedStar Washington Hospital Center, MedStar Heart and Vascular Institute
Washington, District of Columbia, United States

Disclosure(s): Abbott Vascular: Grant/Research Support (Ongoing); Biotronik: Consultant (Ongoing), Grant/Research Support (Ongoing); Boston Scientific Corporation: Consultant (Ongoing), Grant/Research Support (Ongoing); Chiesi USA: Grant/Research Support (Ongoing)

Panel Discussant(s)

Hector M. Garcia-Garcia, MD, PhD

Director of Invasive Imaging Core Laboratory
MedStar Washington Hospital Center
Washington, District of Columbia, United States

No relationships to disclose
Morton J. Kern, MD, MSCAI, FACC, FAHA

Interventional Cardiologist
VA Long Beach Health Care System
Long Beach, California, United States

No relationships to disclose
Bruce Samuels, MD

Interventional cardiologist
Cedars Sinai Medical Center
Beverly Hills, California, United States

No relationships to disclose
Olga Toleva, MD, MPH

Lead of Advanced Coronary Physiology Program
Georgia Heart Institute
Gainesville, Georgia, United States

No relationships to disclose

Disclosure(s):

Gregg W. Stone, MD, FACC, MSCAI: Abbott, Abiomed, Cardiovascular Systems Inc, Phillips, Vascular Dynamics, Pulnovo, V-wave: Research support to Mount Sinai Hospital (Ongoing); Apollo Therapeutics, Cardiac Success, Occlutech, Millennia Biopharma, RCE, Ablative Solutions, Abbott: Consultant (Terminated); Boehringer Ingelheim: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Shockwave, Biosense-Webster, Bioventrix: Research support to Mount Sinai Hospital (Terminated); Valfix, Zoll, HeartFlow, Shockwave, Ancora, Impulse Dynamics, Adona Medical, Oxitope, HighLife, Elixir, Elucid Bio, Aria, Alleviant, FBR Medical: Consultant (Ongoing)

Ron Waksman, MD, MSCAI: Abbott Vascular: Grant/Research Support (Ongoing); Biotronik: Consultant (Ongoing), Grant/Research Support (Ongoing); Boston Scientific Corporation: Consultant (Ongoing), Grant/Research Support (Ongoing); Chiesi USA: Grant/Research Support (Ongoing)

Hector M. Garcia-Garcia, MD, PhD: Abbott Vascular, Medtronic, Boston Scientific: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Morton J. Kern, MD, MSCAI, FACC, FAHA: hemonetics-Opsens: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Medtronics-Cathworks: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Philips; Abbott: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Zoll- Therox: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Bruce Samuels, MD: No financial relationships to disclose

Olga Toleva, MD, MPH: Abbott Labs: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)